KR960010635A - 약제학적 화합물 - Google Patents

약제학적 화합물 Download PDF

Info

Publication number
KR960010635A
KR960010635A KR1019950029475A KR19950029475A KR960010635A KR 960010635 A KR960010635 A KR 960010635A KR 1019950029475 A KR1019950029475 A KR 1019950029475A KR 19950029475 A KR19950029475 A KR 19950029475A KR 960010635 A KR960010635 A KR 960010635A
Authority
KR
South Korea
Prior art keywords
optionally substituted
alkyl
hydrogen
substituted phenyl
trifluoromethyl
Prior art date
Application number
KR1019950029475A
Other languages
English (en)
Inventor
길모어 제레미
태데우스 갤라퍼 피터
빅터 마일스 마틴
마틴 오우튼 윌리암
윌리암 스미스 콜린
Original Assignee
티. 알. 크라우더
릴리 인더스트리즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9418326A external-priority patent/GB9418326D0/en
Priority claimed from GBGB9511166.2A external-priority patent/GB9511166D0/en
Application filed by 티. 알. 크라우더, 릴리 인더스트리즈 리미티드 filed Critical 티. 알. 크라우더
Publication of KR960010635A publication Critical patent/KR960010635A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Optical Integrated Circuits (AREA)

Abstract

하기 일반식(Ⅰ)의 약제학적 화합물 및 이의 염 및 용매화물이 기술되어 있다.
상기 식에서, R1및 R7은 각각 할로, 트리플루오로메틸, C1-6알킬, C1-6알콕시,임의로 치환된 페닐, 임의로 치환된 나프틸 또는 임의로 치환된 헤테로아릴이고, R2및 R3는 각각 수소 또는 C1-6알킬이며, R4및 R5는 각각 수소, 할로, 트리플루오로메틸, C1-6알킬, C1-6알콕시, 임의로 치환된 페닐, 임의로 치환된 나프틸, 암의로 치환된 헤테로아릴, 임의로 치환된 페닐-C1-6알킬 또는 CO2R8(여기서, R8은 에스테르 그룹이다)이며, m및 p 는 각각 0,1,2,3,또는 4이고, Z는또는[여기서, R9및 R10은 각각 수소,C1-6알킬 또는 임의호 치환된 페닐-C1-6알킬이다]이고,X는 산소 또는 황이며, Y 는또는[여기서,R11및 R12는 각각 수소, C1-6알킬, 트리플루오르메틸, 임의로 치환된 페닐, 임의로 치환된 나프틸 또는 임의로 치환된 헤테로아릴이다]이다.

Description

약제학적 화합물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 하기 일반식(Ⅰ)의 약제학적 화합물 및 이의 염 및 용매화물.
    상기 식에서, R1및 R7은 각각 할로, 트리플루오로메틸, C1-6알킬, C1-6알콕시,임의로 치환된 페닐, 임의로 치환된 나프틸 또는 임의로 치환된 헤테로아릴이고, R2및 R3는 각각 수소 또는 C1-6알킬이며, R4및 R5는 각각 수소, 할로, 트리플루오로메틸, C1-6알킬, C1-6알콕시, 임의로 치환된 페닐, 임의로 치환된 나프틸 또는 임의로 치환된 헤테로아릴이고, R6는 수소 C1-6알킬, 임의로 치환된 페닐 임의로 치환된 나프틸, 임의로 치환된 헤테로아릴, 임의로 치환된 페닐-C1-6알킬 또는 CO2R8(여기서, R8은 에스테르 그룹이다)이며, m및 p 는 각각 0,1,2,3,또는 4이고, Z는또는[여기서, R9및 R10은 각각 수소,C1-6알킬 또는 임의호 치환된 페닐-C1-6알킬이다]이고,X는 산소 또는 황이며, Y 는또는[여기서,R11및 R12는 각각 수소, C1-6알킬, 트리플루오르메틸, 임의로 치환된 페닐, 임의로 치환된 나프틸 또는 임의로 치환된 헤테로아릴이다]이다.
  2. 제1항에 있어서, 하기 일반식(Ⅱ)의 화합물.
  3. 제2항에 있어서, X가 산소인 화합물.
  4. 제3항에 있어서,Z가이고, R6가 수소 또는 C1-6알킬인 화합물.
  5. 제1항에 있어서, Z가이고, X가 산소이며, R9가 수소 또는 C1-6알킬이고, m이 0,1 또는 2이며, n이 1 또는 2 이고, R4, R5및 R6가 수소인 화합물.
  6. 하기 일반식의 화합물 및 이의 염.
    상기 식에서, R9는 수소 또는 C1-6알킬이고, R1´,R1˝,R7´및 R7˝은 각각 수소, 할로, C1-6알킬 또는 C1-6알콕시이며, R5는 수소 또는 트리플루오로메틸이고, Y는또는이다.
  7. 제1항에 따른 화합물 또는 이의 약제학적으로 허용되는 염 또는 용매화물을 이의 위한 약제학적으로 허용되는 화석제 또는 담체와 포함하는 약제학적 제형.
  8. 약제로서 사용하기 위한 제1항에 따른 화합물 및 이의 약제학적으로 허용되는 염 또는 용매화물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950029475A 1994-09-12 1995-09-11 약제학적 화합물 KR960010635A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9418326.6 1994-09-12
GB9418326A GB9418326D0 (en) 1994-09-12 1994-09-12 Pharmaceutical compounds
GBGB9511166.2A GB9511166D0 (en) 1995-06-02 1995-06-02 Pharmaceutical compounds
GB9511166.2 1995-06-02

Publications (1)

Publication Number Publication Date
KR960010635A true KR960010635A (ko) 1996-04-20

Family

ID=26305611

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950029475A KR960010635A (ko) 1994-09-12 1995-09-11 약제학적 화합물

Country Status (22)

Country Link
EP (1) EP0705832B1 (ko)
JP (1) JPH0881464A (ko)
KR (1) KR960010635A (ko)
CN (1) CN1045602C (ko)
AT (1) ATE247114T1 (ko)
AU (1) AU698580B2 (ko)
CA (1) CA2157998A1 (ko)
CZ (1) CZ286565B6 (ko)
DE (1) DE69531476T2 (ko)
ES (1) ES2204932T3 (ko)
FI (1) FI954243A (ko)
HU (1) HU219491B (ko)
IL (1) IL115236A (ko)
IN (1) IN179550B (ko)
MY (1) MY132009A (ko)
NO (1) NO305174B1 (ko)
NZ (1) NZ272961A (ko)
PE (1) PE41796A1 (ko)
PH (1) PH31631A (ko)
PL (1) PL310373A1 (ko)
RU (1) RU2146256C1 (ko)
TR (1) TR199501114A2 (ko)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2308362A (en) * 1995-12-19 1997-06-25 Lilly Industries Ltd Pharmaceutical indole derivatives
EP0905136A1 (en) 1997-09-08 1999-03-31 Janssen Pharmaceutica N.V. Tetrahydro gamma-carbolines
UA70334C2 (en) * 1998-10-06 2004-10-15 Janssen Pharmaceutica N V Jans BENZOTHIENO[3,2-c]PYRIDINES AS a2 ANTAGONISTS BENZOTHIENO[3,2-c]PYRIDINES AS a2 ANTAGONISTS
UA74826C2 (en) * 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
AU2001278875B2 (en) * 2000-07-06 2007-06-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tetrahydrobenzothiazole analogues as neuroprotective agents
DE10040016A1 (de) * 2000-08-16 2002-02-28 Boehringer Ingelheim Pharma Neue beta-Amyloid Inhibitoren, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
AU2001293804A1 (en) * 2000-09-19 2002-04-02 Boehringer Ingelheim Pharma Kg New benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
CA2417081C (en) * 2000-09-19 2008-08-05 Enzo Cereda New n, n'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
US6586435B2 (en) 2000-09-19 2003-07-01 Boehringer Ingelheim Pharma Kg Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
WO2003014118A1 (en) * 2001-08-08 2003-02-20 Pharmacia & Upjohn Company THERAPEUTIC 1H-PYRIDO[4,3-b]INDOLES
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
EP1945214A1 (en) 2005-10-29 2008-07-23 Boehringer Ingelheim International GmbH Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
DE602007004615D1 (de) 2006-06-30 2010-03-18 Boehringer Ingelheim Pharma Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
JP5793828B2 (ja) 2006-08-14 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング フリバンセリンの製剤及びその製造方法
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
CN101505736A (zh) 2006-08-25 2009-08-12 贝林格尔.英格海姆国际有限公司 控制释放系统及其制造方法
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
ES2484169T3 (es) 2009-05-29 2014-08-11 Sumitomo Chemical Company, Limited Agente para el tratamiento o la prevención de enfermedades asociadas a la actividad de factores neurotróficos
AU2016331065B2 (en) 2015-10-01 2021-04-29 Olema Pharmaceuticals, Inc. Tetrahydro-1H-pyrido(3,4-b)indole anti-estrogenic drugs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4035369A (en) 1975-10-08 1977-07-12 Janssen Pharmaceutica N.V. 1-Benzazolylalkyl-4-substituted-piperidines
IL69132A (en) * 1982-07-14 1986-02-28 Roussel Uclaf Benzo-and naphtho-thiopyranopyrimidinones,their preparation and pharmaceutical compositions containing them
FR2661177A1 (fr) * 1990-04-23 1991-10-25 Rhone Poulenc Sante Derives du naphtosultame antagonistes de la serotonine, leur preparation et les medicaments les contenant.

Also Published As

Publication number Publication date
HUT72593A (en) 1996-05-28
PH31631A (en) 1999-01-12
ATE247114T1 (de) 2003-08-15
CZ232295A3 (en) 1996-03-13
IL115236A0 (en) 1995-12-31
EP0705832B1 (en) 2003-08-13
RU2146256C1 (ru) 2000-03-10
NO305174B1 (no) 1999-04-12
CZ286565B6 (cs) 2000-05-17
TR199501114A2 (tr) 1996-10-21
EP0705832A1 (en) 1996-04-10
AU3049795A (en) 1996-03-28
PE41796A1 (es) 1996-10-21
NZ272961A (en) 1998-02-26
DE69531476D1 (de) 2003-09-18
NO953575D0 (no) 1995-09-11
CN1045602C (zh) 1999-10-13
AU698580B2 (en) 1998-11-05
CN1129219A (zh) 1996-08-21
HU9502631D0 (en) 1995-11-28
DE69531476T2 (de) 2004-06-09
HU219491B (hu) 2001-04-28
FI954243A (fi) 1996-03-13
IN179550B (ko) 1997-10-18
CA2157998A1 (en) 1996-03-13
IL115236A (en) 1998-06-15
MY132009A (en) 2007-09-28
NO953575L (no) 1996-03-13
PL310373A1 (en) 1996-03-18
ES2204932T3 (es) 2004-05-01
FI954243A0 (fi) 1995-09-11
JPH0881464A (ja) 1996-03-26

Similar Documents

Publication Publication Date Title
KR960010635A (ko) 약제학적 화합물
AU537414B2 (en) Pyroglutamic acid derivatives
KR920702348A (ko) 퀴놀론 카르복실산 유도체
KR960007592A (ko) 신규한 피롤로카바졸
KR940021059A (ko) 지질 대사 개선제
KR890011596A (ko) 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도
KR960006915A (ko) 췌장염의 치료 조성물
KR920701120A (ko) 치환된 비시클로헵탄디온 유도체
ES2129123T3 (es) Nuevo derivado de bisoxadiazolidina.
KR890008136A (ko) 항균성 9-데옥소-9a-알릴 및 프로파길-9a-아자-9a-호모에리트로 마이신 A 유도체
DE3862791D1 (de) N-phenylethylaminoalkyl-benzamide als antiarrhythmische mittel.
KR900701795A (ko) 티에노시클로 헵타피리다진 화합물과 그것의 의약용도
KR940018351A (ko) 노나테트라에노산 유도체
FI872997A0 (fi) Amidderivat.
KR890008151A (ko) 키놀린 카르복산의 유도체
KR870006043A (ko) 피라진유도체 그 제조방법 및 약제조성물
ATE43594T1 (de) 3-alkoxy-2-(n-pyrrolidino)-n-pyridyl-n-furyl(od r thienyl)-methyl-propylamine, ihre herstellung und diese enthaltende pharmazeutische mittel.
KR890003718A (ko) N- 알킬벤젠 술포닐 카르바모일-5- 클로로이소티아졸 유도체 및 살미생물제
ES556048A0 (es) Un procedimiento para la preparacion de un derivado de tiazolidina.
KR970703316A (ko) 4-퀴놀리논 유도체 또는 그의 염(4-quinolinone derivative or salt thereof)
KR920002613A (ko) 이환성 함유 황화합물
KR860007876A (ko) 제초제 조성물
DE69018741D1 (de) Konjugierte gamma-Hydroxybutenolid-Derivate und sie als aktiver Wirkstoff enthaltende Mittel gegen Magengeschwüre.
KR910021373A (ko) 1-페녹시카보닐-2-피롤리디논 유도체 및 향정신성 약제
NO155242C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 4-(substituert alkyl)-n-(1,3-dithiolan-2-yliden) aniliner.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application